Pfizer News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

25.05.22	Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference (Businesswire)
25.05.22	Pfizer Launches ‘An Accord for a Healthier World’ to Improve Health Equity for 1.2 Billion People Living in 45 Lower-Income Countries (Businesswire)
24.05.22	Pfizer Presents ELEVATE Pivotal Findings Demonstrating Etrasimod’s Potentially Best-in-Class Profile in Ulcerative Colitis (Businesswire)
23.05.22	Pfizer-BioNTech COVID-19 Vaccine Demonstrates Strong Immune Response, High Efficacy and Favorable Safety in Children 6 Months to Under 5 Years of Age Following Third Dose (Businesswire)
17.05.22	Pfizer and BioNTech Granted U.S. Emergency Use Authorization for Booster Dose of Their COVID-19 Vaccine in Children 5 Through 11 Years of Age (Businesswire)
17.05.22	Statement of changes in beneficial ownership of securities (RSS)
10.05.22	Pfizer to Acquire Biohaven Pharmaceuticals (Businesswire)
03.05.22	Pfizer Reports First-Quarter 2022 Results (Businesswire)
29.04.22	Form 4 78003 (RSS)
28.04.22	Pfizer Declares Second-Quarter 2022 Dividend (Businesswire)
27.04.22	Pfizer and Biohaven’s VYDURA® (Rimegepant) Granted First Ever Marketing Authorization by European Commission for Both Acute Treatment of Migraine and Prophylaxis of Episodic Migraine (Businesswire)
26.04.22	Valneva and Pfizer Report Positive Phase 2 Pediatric Data for Lyme Disease Vaccine Candidate (Businesswire)
19.04.22	Pfizer Invites Shareholders to Attend Virtual-Only 2022 Annual Meeting of Shareholders on April 28 (Businesswire)
14.04.22	Pfizer and BioNTech Announce Data Demonstrating High Immune Response Following a Booster Dose of their COVID-19 Vaccine in Children 5 Through 11 Years of Age (Businesswire)
14.04.22	Form 4 78003 (RSS)
11.04.22	Pfizer Names David M. Denton Chief Financial Officer (Businesswire)
11.04.22	Additional definitive proxy soliciting materials and Rule 14(a)(12) material (RSS)
07.04.22	Pfizer to Acquire ReViral and Its Respiratory Syncytial Virus Therapeutic Candidates (Businesswire)
07.04.22	Form SC 13D/A 78003 (RSS)
06.04.22	Form DEFA14A 78003 (RSS)
01.04.22	Form 4 78003 (RSS)
29.03.22	Pfizer and BioNTech Receive Expanded U.S. Emergency Use Authorization for an Additional COVID-19 Vaccine Booster in Individuals Aged 50 Years and Older (Businesswire)
29.03.22	Pfizer Announces Positive Top-line Results from Yearlong Phase 3 Trial of Etrasimod in Ulcerative Colitis, Underscoring Best-in-Class Potential (Businesswire)
28.03.22	Initial statement of beneficial ownership of securities (RSS)
24.03.22	Pfizer Granted FDA Breakthrough Therapy Designation for Respiratory Syncytial Virus Vaccine Candidate for the Prevention of RSV in Older Adults (Businesswire)
23.03.22	Pfizer Announces Positive Top-Line Results for Phase 3 Trial of Etrasimod in Ulcerative Colitis Patients (Businesswire)
22.03.22	Pfizer Invites Public to View and Listen to Webcast of May 3 Conference Call with Analysts (Businesswire)
22.03.22	Pfizer to Supply UNICEF up to 4 Million Treatment Courses of Novel COVID-19 Oral Treatment for Low- and Middle-Income Countries (Businesswire)
17.03.22	Form DEF 14A 78003 (RSS)
17.03.22	Additional definitive proxy soliciting materials and Rule 14(a)(12) material (RSS)
11.03.22	Pfizer Completes Acquisition of Arena Pharmaceuticals (Businesswire)
09.03.22	Pfizer Initiates Phase 2/3 Study of Novel COVID-19 Oral Treatment in Pediatric Participants (Businesswire)
08.03.22	Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference (Businesswire)
01.03.22	Phase 3 CLOVER Trial for Pfizer’s Investigational Clostridioides Difficile Vaccine Indicates Strong Potential Effect in Reducing Duration and Severity of Disease Based on Secondary Endpoints (Businesswire)
28.02.22	Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference (Businesswire)
25.02.22	Form 4 78003 (RSS)
24.02.22	Form 10-K 78003 (RSS)
22.02.22	Pfizer Invites Public to View and Listen to Webcast of Pfizer Keynote Presentation at Healthcare Conference (Businesswire)
17.02.22	Form 4 78003 (RSS)
15.02.22	Pfizer and OPKO’s Once-Weekly NGENLA™ (somatrogon) Injection Receives Marketing Authorization in European Union for Treatment of Pediatric Growth Hormone Deficiency (Businesswire)
15.02.22	European Medicines Agency Approves Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease and Pneumonia in Adults (Businesswire)
11.02.22	Pfizer and BioNTech Provide Update on Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of Age (Businesswire)
11.02.22	Form SC 13G/A 78003 (RSS)
09.02.22	Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference (Businesswire)
01.02.22	Pfizer and BioNTech Initiate Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of Age Following Request From U.S. FDA (Businesswire)
01.02.22	Pfizer Announces New Chief Development Officer (Businesswire)
28.01.22	European Commission Approves LORVIQUA® (lorlatinib) as a First-Line Treatment for ALK-Positive Advanced Lung Cancer (Businesswire)
27.01.22	Pfizer Receives CHMP Positive Opinion for Novel COVID-19 Oral Treatment (Businesswire)
25.01.22	Pfizer and BioNTech Initiate Study to Evaluate Omicron-Based COVID-19 Vaccine in Adults 18 to 55 Years of Age (Businesswire)
21.01.22	Pfizer and OPKO Provide Update on the Biologics License Application for Somatrogon for Pediatric Growth Hormone Deficiency (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Zurich Insur Gr	547.60	3.13 %	K V
Logitech Intl	70.26	2.57 %	K V
Givaudan	3’919.00	1.45 %	K V
ABB	49.58	1.08 %	K V
Swiss Re	127.20	0.99 %	K V
Holcim	89.86	-0.24 %	K V
Sika	229.00	-0.35 %	K V
Swisscom	505.50	-0.49 %	K V
Nestle	75.96	-0.73 %	K V
CieFinRichemont	117.65	-0.80 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Pfizer Inc Cert.Deposito Arg.Repr. 0.5 Shs

Aktien Top/Flop

Pfizer Peer Group Nachrichten

Meistgelesene Nachrichten